Inclisiran (Sybrava) is not a substrate, inhibitor or inducer of cytochrome P450 (CYP450) enzymes or common drug transporters, and therefore inclisiran is not expected to have clinically significant interactions with other medications. Drug-drug interaction assessments demonstrated a lack of clinically meaningful interactions with either atorvastatin, rosuvastatin or other statins (see Pharmacology under Actions).